The challenge of sustainability in healthcare systems: cost of radiotherapy in the last month of life in an Italian cancer center

被引:6
作者
Rossi, Romina [1 ]
Danesi, Valentina [2 ]
Massa, Ilaria [2 ]
Balzi, William [2 ]
Romeo, Antonino [3 ]
Foca, Flavia [4 ]
Nanni, Oriana [4 ]
Maltoni, Marco [1 ]
Altini, Mattia [2 ]
机构
[1] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Palliat Care Unit, Via P Maroncelli 40, I-47014 Meldola, FC, Italy
[2] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Healthcare Adm, Via P Maroncelli 40, I-47014 Meldola, FC, Italy
[3] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Radiotherapy Unit, Via P Maroncelli 40, I-47014 Meldola, FC, Italy
[4] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Unit Biostat & Clin Trials, Via P Maroncelli 40, I-47014 Meldola, FC, Italy
关键词
End of life; Radiotherapy; Healthcare sustainability; Healthcare costs; INTENSITY-MODULATED RADIOTHERAPY; EARLY PALLIATIVE CARE; QUALITY-OF-CARE; RADIATION-THERAPY; ECONOMIC-EVALUATION; PROSTATE-CANCER; NECK-CANCER; END; AGGRESSIVENESS; HEAD;
D O I
10.1007/s00520-020-05718-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Cost evaluation is becoming mandatory to support healthcare sustainability and optimize the decision-making process. This topic is a challenge, especially for complex and rapidly evolving treatment modalities such as radiotherapy (RT). The aim of the present study was to investigate the cost of RT in the last month of life of patients in an Italian cancer center. Methods This was a retrospective study on a cancer population (N= 160) who underwent RT or only an RT planning simulation in an end of life (EOL) setting. The cost of RT procedures performed on patients was collected according to treatment status, care setting, and RT technique used. Costs were valued according to the sum of reimbursements relating to all procedures performed and assessed from the perspective of the National Health System. Results The total cost of RT in the last month of life was euro244,774, with an average cost per patient of euro1530. Around 7.7% and 30.3% of the total cost was associated with patients who never started RT or who discontinued RT, respectively, while the remaining 62.0% referred to patients who completed treatment. Costs associated with outpatient and inpatient settings represented 54.3% and 38.6% of the total cost, respectively. The higher average cost per patient for the never-started and discontinued groups was correlated with patients who had a poor ECOG Performance Status. Conclusion Improved prognostic accuracy and a better integration between radiotherapy and palliative care units could be a key to a better use of resources and to a reduction in the cost of EOL RT.
引用
收藏
页码:2735 / 2742
页数:8
相关论文
共 38 条
  • [1] Angelo K, 2014, ANTICANCER RES, V34, P877
  • [2] What is the Quality of Economic Evaluations of Non-Drug Therapies? A Systematic Review and Critical Appraisal of Economic Evaluations of Radiotherapy for Cancer
    Barbieri M.
    Weatherly H.L.A.
    Ara R.
    Basarir H.
    Sculpher M.
    Adams R.
    Ahmed H.
    Coles C.
    Guerrero-Urbano T.
    Nutting C.
    Powell M.
    [J]. Applied Health Economics and Health Policy, 2014, 12 (5) : 497 - 510
  • [3] Role of radiotherapy in cancer control in low-income and middle-income countries
    Barton, Michael B.
    Frommer, Michael
    Shafiq, Jesmin
    [J]. LANCET ONCOLOGY, 2006, 7 (07) : 584 - 595
  • [4] Estimating the cost of radiotherapy for 5-year local control and overall survival benefit
    Batumalai, Vikneswary
    Wong, Karen
    Shafiq, Jesmin
    Hanna, Timothy P.
    Gabriel, Gabriel
    Heberle, Julia
    Koprivic, Ivan
    Kaadan, Nasreen
    King, Odette
    Tran, Thomas
    Cassapi, Lynette
    Forstner, Dion
    Delaney, Geoff P.
    Barton, Michael
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 136 : 154 - 160
  • [5] An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom
    Brown, Ben
    Diamantopoulos, Alexander
    Bernier, Jacques
    Schoeffski, Patrick
    Hieke, Klaus
    Mantovani, Lorenzo
    Launois, Robert
    Griebsch, Ingolf
    Robinson, Paul
    [J]. VALUE IN HEALTH, 2008, 11 (05) : 791 - 799
  • [6] Non-beneficial treatments in hospital at the end of life: a systematic review on extent of the problem
    Cardona-Morrell, M.
    Kim, J. C. H.
    Turner, R. M.
    Anstey, M.
    Mitchell, I. A.
    Hillman, K.
    [J]. INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE, 2016, 28 (04) : 456 - 469
  • [7] Reducing costs at the end of life through provider incentives for hospice care: A retrospective cohort study
    Chen, Bradley
    Kuo, Chin-Chi
    Huang, Nicole
    Fan, Victoria Y.
    [J]. PALLIATIVE MEDICINE, 2018, 32 (08) : 1389 - 1400
  • [8] Cost evaluations of radiotherapy: What do we know? An ESTRO-HERO analysis
    Defourny, Noemie
    Dunscombe, Peter
    Perrier, Lionel
    Grau, Cai
    Lievens, Yolande
    [J]. RADIOTHERAPY AND ONCOLOGY, 2016, 121 (03) : 468 - 474
  • [9] The role of radiotherapy in cancer treatment - Estimating optimal utilization from a review of evidence-based clinical guidelines
    Delaney, G
    Jacob, S
    Featherstone, C
    Barton, M
    [J]. CANCER, 2005, 104 (06) : 1129 - 1137
  • [10] Evaluating claims-based indicators of the intensity of end-of-life cancer care
    Earle, CC
    Neville, BA
    Landrum, MB
    Souza, JM
    Weeks, JC
    Block, SD
    Grunfeld, E
    Ayanian, JZ
    [J]. INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE, 2005, 17 (06) : 505 - 509